Evidence map›Paper›PMID 37176686›Full record

ArticleJournal of clinical medicine2023

Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Scores.

Kirsten E Peters, Scott D Bringans, Ronan S O'Neill, Tasha S C Lumbantobing, James K C Lui, Timothy M E Davis, Michael K Hansen, Richard J Lipscombe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Kirsten E PetersProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.ORCID 0000-0003-1406-8797
Scott D BringansProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.ORCID 0000-0003-4760-9377
Ronan S O'NeillProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.
Tasha S C LumbantobingProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.
James K C LuiProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.
Timothy M E DavisMedical School, The University of Western Australia, Fremantle Hospital, Fremantle, WA 6959, Australia.ORCID 0000-0003-0749-7411
Michael K HansenJanssen Research and Development, LLC, Spring House, PA 19477, USA.ORCID 0000-0002-0062-0520
Richard J LipscombeProteomics International, QEII Medical Centre, 6 Verdun Street, Nedlands, WA 6009, Australia.
Queen Elizabeth II Medical Centre · AUJanssen (United States) · USThe University of Western Australia · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PromarkerD is a biomarker-based blood test that predicts kidney function decline in people with type 2 diabetes (T2D) who may otherwise be missed by current standard of care tests. This study examined the association between canagliflozin and change in PromarkerD score (Δ score) over a three-year period in T2D participants in the CANagliflozin cardioVascular Assessment Study (CANVAS). PromarkerD scores were measured at baseline and Year 3 in 2008 participants with preserved kidney function (baseline eGFR ≥60 mL/min/1.73 m

Indexed as

biomarkerschronic kidney diseasediabetic nephropathykidney declineprognosisrisk predictiontype 2 diabetes

Identifiers

PMID37176686
PMCPMC10179173
OpenAlexW4367627953

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.